Close Menu

kidney cancer

In PLOS this week: potential cystic fibrosis modifiers, potential kidney cancer survival signature, and more.

The Signatera research-use-only assay monitors cancer treatment and assesses minimal residual disease, and is customized for individual patients.

By sequencing 72,501 individual kidney cells, researchers saw some shared transcriptional patterns in kidney cancers and developing or adult kidneys.

Researchers analyzed germline mutations in 256 kidney cancer patients and found mutations that would have been missed, including therapeutically relevant ones.

With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.

The company expects to be able to offer at least one test commercially by the end of this year or early next, with research now starting on two others.

Teams studying kidney and skin cancers independently implicated SWI/SNF chromatin remodeling mutations in checkpoint blockade immunotherapy response.

In Science this week: gut microbes affect how cancer patients respond to immunotherapy, and more.

A pair of papers point to potential gut microbial contributions to checkpoint blockade immunotherapy response in individuals with lung, kidney, or skin cancer.

When investigators retraced recurrent mutations, expression changes, and methylation shifts in hundreds of Wilms tumor case, they identified two main pathways.

Pages

Nebula Genomics will be auctioning George Church's genome as a nonfungible token, according to The Scientist.

Anthony Gregg, the outgoing president of the American College of Medical Genetics and Genomics, has resigned after using racially insensitive language. 

Facebook has developed an artificial intelligence approach to predict how drugs interact in cells, New Scientist reports.

In PNAS this week: adaptations among high-altitude Mycobacterium tuberculosis, response of multiple myeloma cells to chemotherapy-induced stress, and more.